Results 111 to 120 of about 243,350 (258)

A New Paradigm of Bispecific Antibodies in Clinical Management of Gastrointestinal Cancers. [PDF]

Oncol Res
Zhao H, Wang X, Fan Z, Sun A, Zhang C, Sun C.   +5 more
europepmc   +1 more source

CD3 [PDF]

Science-Business eXchange, 2010
openaire   +1 more source

Single‐Cell RNA Editing Identifies T Cell ADAR1 as a Key Regulator of Immune Exhaustion and Anti‐PD‐1 Resistance in Colorectal Cancer

Advanced Science, EarlyView.
Single‐cell RNA editing analysis identifies ADAR1 as a regulator of dysfunctional T cell states in colorectal cancer. Elevated ADAR1 activity promotes T cell exhaustion and impairs antitumor immunity partly through TGF‐β‐SMAD signaling, contributing to anti‐PD‐1 resistance and highlighting T cell ADAR1 as a potential therapeutic target and biomarker ...
Da Kang, Song‐Zuo Xie, Yong‐Zhou Luo, Xin‐Pei Deng, Xi‐Rong Tan, Ze‐Geng Chen, Ling‐Xing Zeng, Gong Chen, Pei‐Rong Ding, Zhi‐Zhong Pan, Rong‐Xin Zhang   +10 more
wiley   +1 more source

Methodological Insights Into T-Cell Activation: CD3/CD28 Versus PMA/Ionomycin Stimulation. [PDF]

Eur J Immunol
Abdulhaqov N, Melo LTA, Meinert I, Fricke S, Simeoni L.   +4 more
europepmc   +1 more source

Targeting a Myeloid–Regulatory B Cell Network Reverses Immune Paralysis in Periprosthetic Joint Infections

Advanced Science, EarlyView.
Periprosthetic joint infection establishes a sophisticated immunosuppressive network between CXCR4+ PMN‐MDSCs and Bregs, inducing profound CD8+ T cell paralysis. Alendronate effectively disrupts this CXCR4+ PMN‐MDSC–Breg axis by targeting STAT3, thereby restoring local immune surveillance.
Jintao Wu, Shutao Zhang, Yumin Lin, Juyang Jiao, Zhiwei Fu, Qimin Hong, Ziyi Zhao, Xinhua Qu, Fei Su, Bing Yue   +9 more
wiley   +1 more source

Engineered Au@CeO2 Hybrid Nanoparticles With Microenvironment Dependent Self‐Adjustability for Integration of Tumor‐Specific Photothermal‐Chemodynamic Therapy and Inflammation Prevention

Advanced Science, EarlyView.
An intelligent Au@CeO2 Hybrid Nanoparticles (ACEF) with microenvironment‐dependent self‐adjustability was engineered to not only perform efficient and tumor‐specific photothermal‐chemodynamic therapy for precise tumor elimination, but also serve as a ROS scavenger in healthy tissues around the tumor to avoid the unexpected oxidative damage and ...
Wenyun Mu, Wenjuan Tang, Handan Zhang, Jie Liu, Jiaqi Zhang, Yu Yao, Xiao Fu, Xin Chen, Yanmin Zhang   +8 more
wiley   +1 more source

Discriminating Post-Transplant Rejection from Infection by Detecting TCR-CD3 Oligomerization on Extracellular Vesicles Using a Ratiometric Caliper Probe. [PDF]

J Am Chem Soc
Yin W, Chen H, Xiao S, Zheng J, Zhao X, Fan L, Lv X, Lv H, Yang Q, Yao J, Yuan X, Yang Y, Yang M.   +12 more
europepmc   +1 more source

Biomimetic Macrophage Cell Membrane‐Based Nanoparticles for Effective Treatment of Glioblastoma Through Boron Neutron Capture Therapy Combined With Immunotherapy

Advanced Science, EarlyView.
ABSTRACT Glioblastoma multiforme (GBM) remains largely incurable due to the blood‐brain barrier (BBB) and immunosuppressive microenvironment. While boron neutron capture therapy (BNCT) selectively eradicates tumor cells via 10B(n, α)‐7Li reactions, its clinical potential in GBM is unrealized because of the suboptimal pharmacokinetics of conventional ...
Jiawen Chen, Haoyu You, Hefa Huang, Huihui Chai, Ruize Zhu, Yun Guan, Qisheng Tang, Tianwen Li, Shan Jiang, Houshi Xu, Peng Wang, Yue Wang, Maoyuan Sun, Beining Liu, Zhen Li, Yulai Zeng, Weiqiu Ping, Yanlin Teng, Songlin Yan, Qinghui Li, Long Gu, Tao Sun, Zhifeng Shi   +22 more
wiley   +1 more source

T-cell engagers in cancer immunotherapy: mechanisms, challenges, and future perspectives. [PDF]

Front Immunol
Muthughavi K, Khokhar M, Jha HC, Pandey RK.   +3 more
europepmc   +1 more source

UBE2O Drives Immune Evasion and Radioimmunotherapy Resistance in Lung Cancer by Degrading CDKL1 to Induce PD‐L1 Transcription

Advanced Science, EarlyView.
UBE2O targets CDKL1 for the degradation to upregulate PD‐L1 expression and promotes resistance to radioimmunotherapy in lung cancer, supporting the potential of targeting UBE2O as a promising therapeutic strategy. ABSTRACT Resistance to radioimmunotherapy is one of the primary causes of treatment failure in lung cancer patients; however, the underlying
Huichan Xue, Xiaohua Jie, Zhiwei Liu, Ruoxin Fang, Shuo Wu, Xiaorong Dong, Shuangbing Xu   +6 more
wiley   +1 more source